Filtering by
![134018-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/134018-Thumbnail%20Image.png?versionId=TjxAXBC_eAycbhJjvIsxKIsVJVfgPEID&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T030536Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=a2f0bec0918e9ea3f058b54dc691770b2ee11b705f5fdbb9337ee705a04e79b3&itok=qMQ-FveV)
![133993-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/133993-Thumbnail%20Image.png?versionId=I7c5_7yRDikvJ3mRUPAsq5Icc_xR31fF&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T024946Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=a9b40efc8453cdc1cb3b4b4201f498012643f7c1f4822d5d4c17f38cae3d89e5&itok=BmrfhBwt)
![135435-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/135435-Thumbnail%20Image.png?versionId=4ug3pGiwCXj6upgzURyh8JYEjaq3Z6ZM&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T063423Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=fe223a0d0c7e525182784576548b44b2d7a6110d5babdc590bd8769a44d5b8a1&itok=onNBDemo)
![152641-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/152641-Thumbnail%20Image.png?versionId=nl9E6KGiGMi3qbn7L9JbvVl3tofdcu.L&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T211717Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=ce9f873a76e4ea7d9c25e25e063ee29b68a74b25d7332d8183158743aae5fc7a&itok=Ch-VMI_e)
![152851-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/152851-Thumbnail%20Image.png?versionId=igvY13jLXQO1YXzVDI6M_h0ZPmSeGP4N&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240617/us-west-2/s3/aws4_request&X-Amz-Date=20240617T065027Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=56165f736ea5fe4a717dc2ba10706bfe8623ec9162ac431b85f1aefa162480ba&itok=wwlBFVGj)
![153110-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/153110-Thumbnail%20Image.png?versionId=qMc.PXv5kIzvOU.h2dA78qdIQHg7OxQP&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T034222Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=fe6e5ee335602e4f35436e84f4d6d256bdfe19e15695de0fa7da22ab59ac5c1c&itok=ShldeDXX)
![153209-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/153209-Thumbnail%20Image.png?versionId=XYUl5jwWTqwOaCQCawceqldjFK2ON7uf&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T150049Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=34bb27fea7449b4fd9c846f56ef7731f93f8e5b00cb0f784cb54e8f801c5ad9d&itok=eHBW65Oi)
The proposed mapping is generalized to express information on a protein's sequence location, structure and function onto a highly localized three-dimensional (3-D) Gaussian waveform. In particular, as analysis of protein homology has shown that incorporating different kinds of information into an alignment process can yield more robust alignment results, a pairwise protein structure alignment method is proposed based on a joint similarity measure of multiple mapped protein attributes. The 3-D mapping allocates protein properties into distinct regions in the time-frequency plane in order to simplify the alignment process by including all relevant information into a single, highly customizable waveform. Simulations demonstrate the improved performance of the joint alignment approach to infer relationships between proteins, and they provide information on mutations that cause changes to both the sequence and structure of a protein.
In addition to the biology-based signal processing methods, a statistical method is considered that uses a physics-based model to improve processing performance. In particular, an externally developed physics-based model for sea clutter is examined when detecting a low radar cross-section target in heavy sea clutter. This novel model includes a process that generates random dynamic sea clutter based on the governing physics of water gravity and capillary waves and a finite-difference time-domain electromagnetics simulation process based on Maxwell's equations propagating the radar signal. A subspace clutter suppression detector is applied to remove dominant clutter eigenmodes, and its improved performance over matched filtering is demonstrated using simulations.
![156114-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/156114-Thumbnail%20Image.png?versionId=3rZZTANJuMM9QeEV0O.Q2BlzVZKOob5M&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240616/us-west-2/s3/aws4_request&X-Amz-Date=20240616T012932Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=e42c439a5fb551e901909bd1d2ebef4238c6e83086b6889ecdcf8654ff21923a&itok=ZIcbtauy)
![156116-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-09/156116-Thumbnail%20Image.png?versionId=ka9TYaLt3qw6uSE_7unqjEBKLP.sxxbc&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T142825Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=6c194263450450d24b33f9f0761e838308081d81c6875edead2805792bc079db&itok=VBIFaRu4)
treatments, and neo-antigens are the targets of immune system in cancer patients who
respond to the treatments. The cancer vaccine field is focused on using neo-antigens from
unique point mutations of genomic sequence in the cancer patient for making
personalized cancer vaccines. However, we choose a different path to find frameshift
neo-antigens at the mRNA level and develop broadly effective cancer vaccines based on
frameshift antigens.
In this dissertation, I have summarized and characterized all the potential frameshift
antigens from microsatellite regions in human, dog and mouse. A list of frameshift
antigens was validated by PCR in tumor samples and the mutation rate was calculated for
one candidate – SEC62. I develop a method to screen the antibody response against
frameshift antigens in human and dog cancer patients by using frameshift peptide arrays.
Frameshift antigens selected by positive antibody response in cancer patients or by MHC
predictions show protection in different mouse tumor models. A dog version of the
cancer vaccine based on frameshift antigens was developed and tested in a small safety
trial. The results demonstrate that the vaccine is safe and it can induce strong B and T cell
immune responses. Further, I built the human exon junction frameshift database which
includes all possible frameshift antigens from mis-splicing events in exon junctions, and I
develop a method to find potential frameshift antigens from large cancer
immunosignature dataset with these databases. In addition, I test the idea of ‘early cancer
diagnosis, early treatment’ in a transgenic mouse cancer model. The results show that
ii
early treatment gives significantly better protection than late treatment and the correct
time point for treatment is crucial to give the best clinical benefit. A model for early
treatment is developed with these results.
Frameshift neo-antigens from microsatellite regions and mis-splicing events are
abundant at mRNA level and they are better antigens than neo-antigens from point
mutations in the genomic sequences of cancer patients in terms of high immunogenicity,
low probability to cause autoimmune diseases and low cost to develop a broadly effective
vaccine. This dissertation demonstrates the feasibility of using frameshift antigens for
cancer vaccine development.
![128958-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/128958-Thumbnail%20Image.png?versionId=tvshD1VebMDZkXhDMmh4L7CJo3ypcNv5&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T220909Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=c5deb9610a0009fde48dbaf759a579b196e5260ad6a2c127a29b5bcbb9fefd57&itok=qLLcjpvx)
Background: Immunosignaturing is a new peptide microarray based technology for profiling of humoral immune responses. Despite new challenges, immunosignaturing gives us the opportunity to explore new and fundamentally different research questions. In addition to classifying samples based on disease status, the complex patterns and latent factors underlying immunosignatures, which we attempt to model, may have a diverse range of applications.
Methods: We investigate the utility of a number of statistical methods to determine model performance and address challenges inherent in analyzing immunosignatures. Some of these methods include exploratory and confirmatory factor analyses, classical significance testing, structural equation and mixture modeling.
Results: We demonstrate an ability to classify samples based on disease status and show that immunosignaturing is a very promising technology for screening and presymptomatic screening of disease. In addition, we are able to model complex patterns and latent factors underlying immunosignatures. These latent factors may serve as biomarkers for disease and may play a key role in a bioinformatic method for antibody discovery.
Conclusion: Based on this research, we lay out an analytic framework illustrating how immunosignatures may be useful as a general method for screening and presymptomatic screening of disease as well as antibody discovery.